Neuromuscular Disease Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Neuromuscular Disease Therapeutics Market Forecast 2024-2028

The global neuromuscular disease therapeutics market size is estimated to grow by USD 9.17 billion, at a CAGR of 11.44% between 2023 and 2028. 

A substantial unmet need exists for neuromuscular disease therapeutics due to the scarcity of approved safe and effective drugs. With over 30 highly morbid and fatal neuromuscular diseases lacking adequate treatment options, the market is constrained by a limited number of approved drugs. Existing treatments often pose severe and multiple side effects. Research in the neuromuscular disease domain is in its early stages, with drugs primarily in early clinical trials or preclinical phases. Focused efforts are directed towards fatal diseases like Duchenne muscular dystrophy and amyotrophic lateral sclerosis, aiming to develop novel therapies, including disease-modifying drugs. Regenerative therapies such as gene and cell therapies offer promising avenues to reverse the damage and enhance patient life expectancy. This unmet need propels the growth of the market during the forecast period. 

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Type, End-user and Geography Analysis

Type Analysis 

The market share growth by the biologics segment will be significant during the forecast period. Biologics are drugs that are either made of living organisms or have certain components of living organisms, such as proteins, monoclonal antibodies, peptides, genes, and cells. The biologics segment of the market consists of approved therapeutics, such as gene therapies and antisense oligonucleotides, for the treatment of various indications and novel biologics, such as cell therapies and monoclonal antibodies, which are being studied in the late stages of clinical trials.

Get a glance at the market contribution of various segments Download PDF Sample

The biologics segment was the largest and was valued at USD 5.12 billion in 2018. However, the increasing prices of gene therapies are expected to pose a major threat to the growth of this segment during the forecast period. Despite the presence of various patient assistance programs available for the treatment of spinal muscular atrophy, the high costs associated with the treatment using these therapies keep the financial burden on patients high. Nevertheless, there have been growing incidences of muscle and nerve problems in the body and increasing approval of new biologics by regulatory authorities. For instance, in January 2024, Takeda announced that its HYQVIA, subcutaneous immunoglobulin received FDA approval for maintenance therapy of rare neuromuscular disorder. Such developments are expected to fuel the growth of the biologics segment, which will thereby drive the growth of the market during the forecast period.

End-user Analysis 

Hospitals held the largest market share by end-users in the market in 2023. The hospitals segment of the market in focus is expected to maintain its dominance. Hospitals are a significant segment of the market since they are the main locations where neuromuscular disease treatments are carried out and patients receive medical attention. Moreover, amyotrophic lateral sclerosis (ALS) is also fueling at a rapid rate, especially in the US. Thus, the growing cases of neuromuscular diseases are driving hospital visits for various tests and pain management, which, in turn, will fuel the growth of the market during the forecast period.

Clinics held the second-largest market share by end-users in the market in 2023. The clinics segment is expected to grow during the forecast period. Clinics are crucial healthcare institutions where patients undergo a variety of medical procedures. Clinics frequently act as alternative locations for patients to visit. Genetic mutation, viral infection, hormonal disorders, dietary deficiency, and more are the causes of neuromuscular disorders, and their diagnosis and treatment include a variety of tests, which fuels the demand for clinics as these provide convenience in testing services. As the neuromuscular disease has no complete treatment, the clinic provides medical therapy, such as immunosuppressive drugs, to enhance the quality of life. Thus, owing to convenience and accessibility, the clinics segment is expected to grow, which, in turn, will positively affect the growth of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and drivers will shape the market during the forecast period. This is primarily attributed to the increasing prevalence of neuromuscular diseases and the availability of highly advanced therapeutics for the treatment of these diseases.  The highly fatal nature of spinal muscular atrophy and the rising need for a highly effective therapy for curing the indication has resulted in the market witnessing advanced research on the use of gene therapies for the treatment of the indication. For instance, in August 2020, the US Food and Drug Administration approved Evrysdi (risdiplam) to treat people with SMA who are above two months old, a rare and frequently fatal genetic condition that affects muscle strength and movement. The market in the region has also witnessed multiple approvals, including biologics and small molecule-based drugs, for the treatment of Duchenne muscular dystrophy, such as Exondys 51.

In addition, factors such as the increasing number of special drug designations, such as the orphan drug designation and the fast-track designation, are contributing to the growth of the market. The market is also expected to benefit significantly from newborn screening tests, which will result in the early diagnosis of most of the neuromuscular diseases. Owing to these factors, the market in North America is expected to witness an accelerating growth momentum during the forecast period.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc. - The company offers neuromuscular disease therapeutics such as Levodopa Infusion therapy, used for the treatment of advanced Parkinson's disease in adults.

• Aquestive Therapeutics Inc.
• argenx SE
• AstraZeneca PLC
• Biogen Inc.
• CuraVac
• F. Hoffmann La Roche Ltd.
• Grifols SA
• Merck and Co. Inc.
• Nippon Shinyaku Co. Ltd.
• Novartis AG
• Pfizer Inc.
• Roivant Sciences Ltd.
• Santhera Pharmaceuticals Holding AG
• Sarepta Therapeutics Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Key Dynamics and Customer Landscape

The market is propelled by the rising aging demographic, leading to increased cases of musculoskeletal disorders and Skeletal Muscle (SkM). The use of neuromuscular blocking agents and muscle relaxants in surgeries and artificial ventilation contributes to market growth. However, side effects such as sedation and paralysis pose challenges. The prevalence of musculoskeletal issues emphasizes the need for awareness, prompting advancements like technologically improved neuromuscular blockades including Dysport for conditions like upper limb spasticity in cerebral palsy. Customer awareness and effective treatment and management trends are pivotal for market progression. There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Drivers

Increasing research on developing therapeutics for neuromuscular diseases, particularly in the context of the elderly populations affected, is notably driving market growth. This emphasis is crucial due to the complex nature of these diseases, which often involve the prevalence of musculoskeletal disorders. The growing prevalence of neuromuscular diseases, including cases related to heart failure and necessitating research on identifying targets, has attracted various researchers and organizations. The market also witnesses multiple organizations providing funding for the research on Duchenne muscular dystrophy, such as the Muscular Dystrophy Association focusing on potential cures and therapies. This includes tackling challenges like sedation, paralysis, and side effects associated with neuromuscular diseases.

Moreover, the increasing research funding opportunities in the market are expected to encourage various small- and mid-sized vendors and researchers to develop potential cures for neuromuscular diseases, considering factors like physicians, heavy machinery, and customer awareness. This concerted effort aims at effective treatment and management, exploring advancements such as technologically improved neuromuscular blockades, exemplified by products like Dysport injections, particularly beneficial in cases of upper limb spasticity and cerebral palsy. The collaborative endeavors and research initiatives encompass various aspects, from understanding the prevalence of musculoskeletal issues to exploring innovative solutions for artificial ventilation in surgical settings. This collective approach anticipates augmenting the growth of the market during the forecast period.

Significant  Trends

Increasing research on developing therapeutics for neuromuscular disease for neuromuscular disease is an emerging trend influencing market growth. This is primarily due to the complex nature of these diseases, which demands research on identifying the targets and the development of a potential treatment or cure for these diseases. The growing prevalence of neuromuscular diseases and the strong growth opportunities in the market have attracted various researchers and organizations to research developing therapeutics for these indications. The market also witnesses multiple organizations providing funding for the research on Duchenne muscular dystrophy.

For instance, the Muscular Dystrophy Association, one of the largest nonprofit organizations focusing on the research of a potential cure for Duchenne muscular dystrophy, has provided more than USD 1 billion in funding to accelerate the discovery of therapies and cures since its inception. Thus, the increasing research funding opportunities in the market are expected to encourage various small- and mid-sized companies and researchers to develop a potential cure for neuromuscular diseases. This is expected to augment the growth of the market during the forecast period.

Major  Challenges

Loss of patents and patent expiry is a significant challenge hindering market growth. Loss of patents and market exclusivity of drugs create opportunities for the sales of low-cost alternative drugs, which may decrease the sales of approved drugs. Currently, the market has two drugs, which can delay the progression of the disease and are approved for the treatment of neuromuscular disease. Generic drugs are those drugs that are similar to branded drugs in terms of quality, dosage form, strength, and efficacy but are available at lower prices. Generic penetration limits market growth as the drugs become available at lower prices.

For instance, on 27 February 2024, Merck, in an SEC filing disclosed that Hikma Pharmaceuticals US is seeking the FDA's approval for its generic version of the muscle relaxant reversal injection Bridion (sugammadex) prior to the drug's patent expiration. Patent expiration of branded drugs will result in generic drugs reducing the sales of branded drugs, which can negatively affect the business of prominent companies. Thereby hindering the growth prospect of the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market forecasting report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Type Outlook
  • Biologics
  • Small molecules

• End-user Outlook
  • Hospitals
  • Clinics
  • Others
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia

Market Analyst Overview

The Neuromuscular Disease Therapeutics Market is experiencing growth due to various factors, including an aging population and the increasing prevalence of musculoskeletal disorders. These disorders, such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD), require advanced treatments like neuromuscular blocking agents and muscle relaxants. However, these therapies can have side effects like dry mouth, tiredness, and dizziness. Despite these challenges, there is a high demand for technologically improved neuromuscular blockades and effective management options for conditions like upper limb spasticity and cerebral palsy. The market's expansion is also driven by customer awareness and investments in treatment advancements for diseases like Neuromuscular Junction (NMJ), myotonic dystrophy (DM) and spinal muscular atrophy (SMA).

Moreover, the market is witnessing growth due to factors like an aging population and increasing disease prevalence. Demyelinating disease therapeutics play a crucial role in addressing conditions such as myasthenia gravis (MG), Pompe disease, and congenital myasthenic syndromes (CMS), impacting both motor neurons (MNs) and the cerebral cortex. With varying incidence rates and adult prevalence, these diseases can lead to depression and necessitate the use of pharmaceutical and biopharmaceutical drugs for management. The disorders affect both upper motor neurons (UMNs) and lower motor neurons (LMNs), disrupting function in pre-motor and primary motor regions. Surgical interventions and medications targeting acetylcholine play a crucial role in managing these conditions. However, there are challenges such as adverse side effects and the high investment required for research and development. The market expansion is also driven by the demand for remedies for conditions like lower back pain and demyelinating diseases. Despite the nonspecific burden in industrialized countries, advancements in therapies using hiPSCs (Human Induced Pluripotent Stem Cells) offer promising solutions. Strict regulatory norms and the availability of raw materials are also influencing market dynamics.

Market Scope
Report Coverage	Details
Page number	165
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 11.44%
Market Growth 2024-2028	USD 9.17 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	10.23
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 43%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Aquestive Therapeutics Inc., argenx SE, AstraZeneca PLC, Biogen Inc., CuraVac, F. Hoffmann La Roche Ltd., Grifols SA, Merck and Co. Inc., Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Roivant Sciences Ltd., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd.
Market dynamics	Parent market growth analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size and its contribution to the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch